PRIVATE FUNDING OPPORTUNITIES: AUG 17, 2018

Please contact Corporate & Foundation Relations in the Office of Development at devcfr@mgh.harvard.edu if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

1. CARRA-Arthritis Foundation Large Grants, Childhood Arthritis and Rheumatology Research Alliance CARRA New

This funding opportunity supports the development and publication of a clinical or translational project which will immediately impact research projects within CARRA or result in a larger collaborative grant that furthers the CARRA mission. New or early investigators are encouraged to apply and will be afforded special consideration. A successful application may be for:

- an all-inclusive clinical or translational research project; or
- a pilot research project, that if successful, could lead to extramural funding.

Citizenship: Unrestricted

Award Amount: $50,000 for 1 year
Indirect Costs: 8%
LOI Deadline: Sep 1, 2018
Application Deadline: Oct 1, 2018
Website: https://carragroup.org/members/grants-and-funding/carra-af-large-grants

2. LeRoy Matthews Physician-Scientist Award, Cystic Fibrosis Foundation (CFF)

The LeRoy Matthews Physician-Scientist Award was established by CFF to honor and in memory of Dr. LeRoy Matthews’ dedication and commitment to CF research and care. The award encourages outstanding newly trained pediatricians and internists to enhance clinical proficiency in CF-related sub specialties and to develop the necessary research capabilities to become independent biomedical investigators.

Do you want to learn more about identifying external funding opportunities? See ECOR’s website for information on the funding opps database, COS Pivot or contact Amy Robb <arobb@mgh.harvard.edu> to schedule an individual consultation or group training session.
The award provides individuals who are either enrolled in or are about to enroll in sub specialty training with the opportunity to undertake up to six (6) years of support for their clinical training, research training, and the initiation of their research career. It is anticipated that the award will provide the opportunity for clinicians to obtain sub specialty training, to develop into independent investigators, and to initiate a research program.

Citizenship: United States

Award Amount: Support ranges from $60,000 (stipend) plus $10,000 (research and development) for year one, to $100,000 (stipend) plus $30,000 (research and development) for year six.
Indirect Costs: None
Application Deadline: Feb 19, 2019

3. Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation (CFF)

The Harry Shwachman CF Clinical Investigator Award provides the opportunity for promising, clinically-trained physicians with a commitment to research to develop into independent biomedical researchers who have active involvement in CF-related areas. The award helps facilitate the transition from postdoctoral training to an academic career as an independent investigator. The award enables candidates to undertake three years of research, tailored to the individual’s interests and needs, with a sponsor(s) who is/are competent to provide appropriate research guidance and supervision.

Citizenship: United States

Award Amount: $330,000 paid over 3 years
Indirect Costs: None
Application Deadline: Feb 15, 2019
Website: https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Career-Development-Awards/Harry-Shwachman-Clinical-Investigator-Award/

4. Prader-Willi Syndrome Research, Foundation for Prader-Willi Research (FPWR)

FPWR is pleased to announce two special priority areas for the Fall 2018 grant cycle:
1. Brain Imaging Studies in Individuals with PWS
Despite a growing number of brain imaging studies suggesting altered functional connectivity in individuals with PWS, the precise patterns of the network abnormalities in PWS are still unknown. Identification of specific connectivity patterns of brain network disturbances characteristic of PWS across development or when PWS symptoms first emerge and manifest are needed to further our understanding of the neurodevelopmental abnormalities in PWS.
Thus, FPWR is interested in proposals that apply cutting-edge functional brain imaging to examine connectivity in individuals with PWS at specific developmental stages or across development. The scope of this RFA is broad, encompassing descriptive studies or focusing on the neurobiological correlates underlying phenotypic abnormalities characteristics of PWS such as hyperphagia and mental health.

2. Genetic Therapy for PWS
Proposals submitted to this special priority area should focus on establishing early proof-of-concept, and should address one or more of the following questions aimed at determining the feasibility of gene activation or gene replacement therapies for PWS.

- Does activation/replacement of PWS genes reverse the PWS phenotype in cellular models and/or animal models of PWS?
- Which gene(s) need to be targeted?
- What organs and cell types need to be targeted?
- What level of expression needs to be achieved to have a therapeutic effect?
- Is there a critical window for genetic therapy? At which point during development does gene activation/replacement need to occur to achieve a therapeutic effect? Do different aspects of the phenotype have different critical periods?
- What are on target side effects? How is expression of UBE3a affected?
- What are off target side effects?
- Can delivery of the therapeutic molecule be achieved / what is the best delivery system?

Citizenship: Unspecified

Award Amount: $100,000-$150,000 for 1 year; a second year of funding upon competitive renewal is possible
Indirect Costs: 8%
LOI Deadline: Sep 17, 2018
Full Proposal Deadline: Nov 16, 2018
Website: [http://www.fpwr.org/request-for-applications/](http://www.fpwr.org/request-for-applications/)

5. The Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research: Junior Faculty, Health Resources in Action (HRiA)/The Medical Foundation
The primary goal of the new Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research is to support innovative, clinically relevant research that seeks to understand the underlying biology of eating disorders, including anorexia nervosa and bulimia nervosa, leading to improved patient care. Clinical trials, obesity research, and binge eating research are outside the scope of the program.

The Davis Foundation Awards Program is a two-stage proposal process. All applicants will submit an Initial Proposal. Based upon the review results, invited applicants will receive instruction to submit a Full Proposal.
Citizenship: Unrestricted

Award Amount: $200,000 paid over 2 years
Indirect Costs: 5%
Initial Proposal Deadline: Sep 28, 2018
Website: https://hria.org/tmf/DavisJunior/

6. The Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research: Senior Postdoctoral Fellows, Health Resources in Action (HRiA)/The Medical Foundation
The primary goal of the new Hilda and Preston Davis Foundation Awards Program for Eating Disorders Research is to support innovative, clinically relevant research that seeks to understand the underlying biology of eating disorders, including anorexia nervosa and bulimia nervosa, leading to improved patient care. Clinical trials, obesity research, and binge eating research are outside the scope of the program.

Applicants must have completed at least three (3) years and no more than seven (7) years of full-time postdoctoral research experience.

The Davis Foundation Awards Program is a two-stage proposal process. All applicants will submit an Initial Proposal. Based upon the review results, invited applicants will receive instruction to submit a Full Proposal.

Citizenship: Unrestricted

Award Amount: Estimated to be $110,000 paid over 2 years; award amount to be adjusted based upon awardee experience and will be comparable to current NIH fellowship levels
Indirect Costs: None
Initial Proposal Deadline: Sep 28, 2018
Website: https://hria.org/tmf/DavisFellow

7. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme, International AIDS Society (IAS)
The CIPHER Grant Programme directly supports the development of early-stage investigators, awarding grants to address research gaps in paediatric and adolescent HIV in resource-limited settings.

CIPHER has three primary objectives:

- Promote and invest in targeted research to address priority knowledge gaps in paediatric HIV
- Convene stakeholders and facilitate collaboration to strengthen communication, knowledge transfer and exchange among paediatric HIV cohorts
• Undertake advocacy to support evidence-informed clinical, policy and programmatic decision making.

Eligible Research Priorities
The research funded by the CIPHER Grant Programme should focus on operation science in paediatric HIV and address crucial gaps in paediatric HIV research that impede optimal HIV diagnosis, treatment and care for infants and children affected by HIV in resource-limited settings.

Eligible research projects include original research that falls within defined priority research questions. Meta-analyses and systematic reviews will also be considered if they make unique contributions to the outlined questions.

Paedriatic HIV (infants and children 0–10 years old, including the perinatal and in-utero period, studies on mother-baby pairs and HIV-exposed uninfected children)

Testing
• Optimal placement and timing of novel diagnostic tools for point-of-care use;
• Interventions to ensure timely linkage between HIV diagnosis, treatment and care;
• Interventions or strategies to improve access to and uptake of HIV testing services for infants and children, particularly community-based approaches;
• Factors that enable or hinder linkage to care and timely initiation of ART;
• Effective, feasible and acceptable testing strategies (including routine testing at birth) at entry points other than antenatal care for identifying undiagnosed HIV-positive infants and children in different epidemic settings.

Treatment
• Safety, efficacy, acceptability, pharmacokinetics and optimal dosing of existing and new antiretroviral drugs and formulations, particularly with novel drug delivery systems;
• Strategies or interventions to improve adherence, and factors that impact their success;
• Optimal prevention and clinical management of co-infections, particularly tuberculosis;
• Impact of HIV infection and ART on short- and long-term outcomes, in particular non-communicable disease;
• Short- and long-term virologic and immunologic outcomes of starting very early treatment in infants living with HIV (impact on functional cure).

Service Delivery
• Strategies or interventions to improve access to, uptake of and retention in care, and factors that impact their success;
• Service delivery models to improve individual and programmatic outcomes along the HIV cascade, including integration of comprehensive HIV treatment and care into the maternal and child health platform;
• Psychosocial and family support strategies or interventions to improve individual and programmatic outcomes;
• Strategies or interventions to improve and support parents, caregivers and healthcare providers to facilitate HIV disclosure to children, as well as factors that impact their success;
• Strategies or interventions to reduce stigma and discrimination experienced by children and their caregivers.

The CIPHER Grant Programme encourages collaborations between different study sites and institution.

Applications are encouraged from any country, but approximately 80 percent of available funds in any given year will be awarded to applicants from (meaning holding a passport from) low- and middle-income countries (LMICs) according to the World Bank classification.

Citizenship: Unrestricted

Award Amount: $150,000 paid over 2 years
Indirect Costs: 10%
LOI Deadline: Oct 26, 2018
(Invited) Application Deadline: Jan 25, 2019
Website: https://www.iasociety.org/HIV-Programmes/Programmes/Paediatrics-CIPHER/CIPHER-Grant-Programme

8. Established Investigator Awards, Melanoma Research Alliance (MRA)
Established Investigator Awards support senior investigators with an established record of scientific productivity and accomplishment.

MRA is soliciting proposals that address the gap in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and melanoma patients). Successful proposals have the potential of applying important basic and preclinical discoveries to the near-term development of clinical trials and studies impacting melanoma detection, prevention, diagnosis, staging, and/or treatment. Proposals for clinical studies testing well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline with milestones. IRB approval is not required at the time of application but is required before initial payments are made. MRA welcomes proposals in the following areas:
• Prevention: Elucidation of environmental, epidemiological, and biological factors in melanomagenesis that lead to prevention strategies.
• Detection, Diagnosis, and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
- Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include, but are not limited to, studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas: For the 2018-2019 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:

- Identifying strategies to overcome resistance, treatment failure, and/or difficult-to-treat melanoma subtypes such as acral, mucosal or uveal melanoma
- Informing logical and optimal combination therapies, therapeutic sequences, and/or treatment regimens including adjuvant and neoadjuvant approaches
- Developing strategies to prevent and/or treat metastatic disease
- Identifying markers of response, resistance, and/or risk of recurrence or death
- Improving prevention and early detection strategies by understanding of the biological basis for melanoma formation and/or developing new diagnostic approaches

Citizenship: Unrestricted

Award Amount: $375,000 paid over 3 years
Indirect Costs: None
Full Proposal Deadline: Nov 2, 2018
Website: http://www.curemelanoma.org/research/request-for-proposals/

9. Pilot Award, Melanoma Research Alliance (MRA)
Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such "high-risk, high-reward" projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

MRA is soliciting proposals that address the gap in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and melanoma patients). Successful proposals have the potential of applying important basic and preclinical discoveries to the near-term development of clinical trials and studies impacting melanoma detection, prevention, diagnosis, staging, and/or treatment. Proposals for clinical studies testing well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline with milestones. IRB approval is not required at the time of application but is required before initial payments are made. MRA welcomes proposals in the following areas:
• Prevention: Elucidation of environmental, epidemiological, and biological factors in melanomagenesis that lead to prevention strategies.
• Detection, Diagnosis, and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
• Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include, but are not limited to, studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas: For the 2018-2019 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:
• Identifying strategies to overcome resistance, treatment failure, and/or difficult-to-treat melanoma subtypes such as acral, mucosal or uveal melanoma
• Informing logical and optimal combination therapies, therapeutic sequences, and/or treatment regimens including adjuvant and neoadjuvant approaches
• Developing strategies to prevent and/or treat metastatic disease
• Identifying markers of response, resistance, and/or risk of recurrence or death
• Improving prevention and early detection strategies by understanding of the biological basis for melanoma formation and/or developing new diagnostic approaches

Citizenship: Unrestricted

Award Amount: $100,000 paid over 2 years
Indirect Costs: None
Full Proposal Deadline: Nov 2, 2018
Website: http://www.curemelanoma.org/research/request-for-proposals/

10. Special Opportunity: ASTRO-MRA Early Career Investigator Award in Radiation Oncology, Melanoma Research Alliance (MRA)  New
Research in radiation oncology has led to advancements in technology and therapy that have improved patient outcomes and care. The MRA is pleased to partner with the American Society for Radiation Oncology (ASTRO) to offer a special opportunity to support research in radiation oncology to improve treatment options for melanoma patients. Early career radiation oncologists, radiation or cancer biologists, or physicists are encouraged to submit radiation oncology Research Proposals that include at least 50% effort on melanoma.

Citizenship: United States
Award Amount: $200,000 paid over 3 years
The award also requires a match of $100,000 from the awardee's institution, either in matching funds or in-kind contribution. This could include facilities and administration costs (F&A), dedicated research time, or other costs covered by the institution. The matching funds can be supplied over the full timeframe of the grant.
Indirect Costs: None
Applicant Eligibility Checklist Deadline: Oct 19, 2018
Full Proposal Deadline: Nov 2, 2018
Website: https://www.curemelanoma.org/research/request-for-proposals/

11. Special Opportunity: Bristol-Myers Squibb-MRA Young Investigator Awards in Immunotherapy, Melanoma Research Alliance (MRA) New
Through the generous support of Bristol-Myers Squibb (BMS), MRA is offering two awards for Young Investigators to conduct projects supported by preliminary data and focused on advancing immunotherapies in melanoma.

Citizenship: Unrestricted

Award Amount: $225,000 paid over 3 years
Indirect Costs: None
Applicant Eligibility Checklist Deadline: Oct 19, 2018
Full Proposal Deadline: Nov 2, 2018
Website: https://www.curemelanoma.org/research/request-for-proposals/

12. Special Opportunity: MRA Young Investigator Award and MRA Established Investigator Awards for Artificial Intelligence Applied to Melanoma, Melanoma Research Alliance (MRA) New
Advances in artificial intelligence (AI) are rapidly impacting the oncology landscape, with potential applications in target identification and development, medical and diagnostic imaging, prognostics and clinical decision making, among others. MRA seeks to support research efforts that use AI to advance melanoma detection, prevention, diagnosis, staging, and/or treatment by offering two AI-focused Established Investigator Awards and one Young Investigator Award.

While any proposal that applies AI to melanoma will be considered, priority will be given to proposals addressing following applications:

- Melanoma diagnosis: Improving the detection and/or diagnosis of melanoma from digital images, including dermatopathology images
- Prognostic indicators for melanoma patient outcomes: Analyzing diverse datasets to identify novel biomarkers for patient prognosis and/or response to treatment
• Discovery of novel drug targets: Identifying novel drug candidates for melanoma through AI-driven data analysis

Citizenship: Unrestricted

Award Amount:
• Young Investigator Awards are up to $225,000 paid over 3 years
• Established Investigator Awards are up to $375,000 paid over 3 years
Indirect Costs: None
Applicant Eligibility Checklist Deadline (Young Investigator applicants only): Oct 19, 2018
Full Proposal Deadline: Nov 2, 2018
Website: https://www.curemelanoma.org/research/request-for-proposals/

13. Special Opportunity: MRA Young Investigator Award and MRA Established Investigator Award in Dermatology, Melanoma Research Alliance (MRA) New
With this Special Opportunity, MRA is offering one Young Investigator Award and one Established Investigator Award to support academic research carried out by dermatology faculty. Research proposals can focus on prevention, diagnosis, and/or treatment of melanoma, and may include research related to dermatology, dermatopathology, and/or dermatologic surgery.

Citizenship: Unrestricted

Award Amount:
• Young Investigator Awards are up to $225,000 paid over 3 years
• Established Investigator Awards are up $375,000 paid over 3 years
Indirect Costs: None
Applicant Eligibility Checklist Deadline (Young Investigator applicants only): Oct 19, 2018
Full Proposal Deadline: Nov 2, 2018
Website: https://www.curemelanoma.org/research/request-for-proposals/

14. Young Investigator Awards, Melanoma Research Alliance (MRA)
Young Investigator Awards aim to attract early career faculty with original ideas into the field of melanoma, thereby recruiting and supporting the next generation of melanoma research leaders. Awardees will be provided funding to accomplish innovative and original, preclinical, translational, and/or early clinical research projects.

MRA is soliciting proposals that address the gap in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and melanoma patients). Successful proposals have the potential of applying important basic and preclinical discoveries to the near-term development of clinical trials and studies impacting melanoma detection,
prevention, diagnosis, staging, and/or treatment. Proposals for clinical studies testing well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline with milestones. IRB approval is not required at the time of application but is required before initial payments are made. MRA welcomes proposals in the following areas:

- Prevention: Elucidation of environmental, epidemiological, and biological factors in melanomagenesis that lead to prevention strategies.
- Detection, Diagnosis, and Staging: Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.
- Treatment: Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include, but are not limited to, studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas: For the 2018-2019 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:

- Identifying strategies to overcome resistance, treatment failure, and/or difficult-to-treat melanoma subtypes such as acral, mucosal or uveal melanoma
- Informing logical and optimal combination therapies, therapeutic sequences, and/or treatment regimens including adjuvant and neoadjuvant approaches
- Developing strategies to prevent and/or treat metastatic disease
- Identifying markers of response, resistance, and/or risk of recurrence or death
- Improving prevention and early detection strategies by understanding of the biological basis for melanoma formation and/or developing new diagnostic approaches

Citizenship: Unrestricted

Award Amount: $225,000 paid over 3 years
Indirect Costs: None
Application Eligibility Checklist Deadline: Oct 19, 2018
Full Proposal Deadline: Nov 2, 2018
Website: https://www.curemelanoma.org/research/request-for-proposals/

15. NVA Medical Research Fund, National Vulvodynia Association (NVA)
The NVA is seeking research proposals on the causes or treatment of Generalized Vulvodynia. Grants made through NVA’s Medical Research Fund provide scientists with the opportunity to gather vital pilot data, which they need to secure funding from larger institutions, such as the National Institutes of Health (NIH). Many of our grant recipients have been successful in obtaining multi-million grants from the NIH and other institutions.
16. Improved Biomarkers and Clinical Outcome Measures Program, The Michael J. Fox Foundation for Parkinson’s Research (MJFF)

The Michael J. Fox Foundation (MJFF) seeks to support research that will develop biomarker tools and clinical outcome measures to assist in diagnosis and therapeutic development and ultimately inform clinical trial design, execution and interpretation of results. Part of our Edmond J. Safra Core Programs for PD Research, the Improved Biomarker and Clinical Outcome Measure program funds research to develop or optimize imaging, clinical, non-invasive or biochemical biomarkers.

Funding will be directed to projects that will improve the precision of measuring Parkinson’s disease in humans. This could include enriching subject populations in clinical trials, developing markers of target engagement, or discovery or validation of objective outcomes that track disease progression.

Applications must focus on developing robust and precise biomarker measures (e.g., imaging, physiological or biochemical assays), clinical outcome measures, and/or scale development (e.g. predictive modeling) for PD.

Citizenship: Unrestricted

Award Amount: Up to $750,000 paid over 1-3 years
Indirect Costs: 25%
Pre-Proposal Deadline: Sep 26, 2018
(Invited) Full Proposal Deadline: Jan 22, 2019
Website: https://www.michaeljfox.org/research/grant-detail.php?id=29

17. Target Advancement Program, The Michael J. Fox Foundation for Parkinson’s Research (MJFF)

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson’s disease (PD) is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the advancement of innovative therapies for Parkinson’s patients. Part of our
Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson’s treatments.

Target Advancement awards support research characterizing promising, novel PD-relevant targets or continuing target biology work on established PD targets. Preferred targets for this program already demonstrate links to PD in human patient populations. These awards are well-suited to projects in which hypothetical or experimental rationale for a target is compelling but limited, and study results can make the case for continuing (or discontinuing) a line of research.

Citizenship: Unrestricted

Award Amount: Up to $150,000 paid over 12-18 months
Indirect Costs: 25%
Pre-Proposal Deadline: Sep 26, 2018
(Invited) Full Proposal Deadline: Jan 22, 2019
Website: https://www.michaeljfox.org/research/grant-detail.php?id=27